MIBE
Jump to navigation
Jump to search
Identifiers | |
---|---|
| |
Chemical and physical data | |
Formula | C21H25NO5 |
Molar mass | 371.433 g·mol−1 |
3D model (JSmol) | |
| |
|
MIBE is a synthetic, nonsteroidal antiestrogen that acts as a dual antagonist of the ERα and the GPER.[1][2] It was found to prevent estradiol-induced proliferation of MCF-7 breast cancer cells, an action that was mediated via inhibition of both receptors.[1][2] The drug was synthesized in 2012.[1] It has been suggested that drugs like MIBE might be superior agents in the treatment of breast cancer compared to current antiestrogens like tamoxifen and fulvestrant, which are antagonistic at the ERα but were found in 2005 to be GPER agonists.[1][2]
References
- ^ a b c d Lappano R, Santolla MF, Pupo M, Sinicropi MS, Caruso A, Rosano C, Maggiolini M (2012). "MIBE acts as antagonist ligand of both estrogen receptor α and GPER in breast cancer cells". Breast Cancer Res. 14 (1): R12. doi:10.1186/bcr3096. PMC 3496129. PMID 22251451.
- ^ a b c Rosano C, Lappano R, Santolla MF, Ponassi M, Donadini A, Maggiolini M (2012). "Recent advances in the rationale design of GPER ligands". Curr. Med. Chem. 19 (36): 6199–206. doi:10.2174/092986712804485755. PMID 23116143.
Categories:
- Articles with short description
- Short description matches Wikidata
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Antiestrogens
- GPER antagonists
- Enones
- Esters
- Indole ethers at the benzene ring
- Ethyl esters
- All stub articles
- Genito-urinary system drug stubs